 |
| A/Prof Matt McCormack (right) answering a question with A/Prof David Curtis, Chair of the session, alongside at Australian Centre for Blood Diseases (ACBD)'s recent annual symposium. Matt has recently moved to ACBD and his group works particularly on understanding the roles of transcription factors in normal and leukaemic hematopoiesis. See more about Matt's lab. |
Introduction: Prof Harshal Nandurkar, Director, ACBD
Session 1 Chair: A/Prof Ross Dickins
- Dr Giovanni Monaco: The therapeutic targeting of metabolic vulnerabilities in acute myeloid leukaemia (AML)
- Dr Zoe McQuilten: Clinical transfusion research in critical care and haematology
- A/Prof Jake Shortt: Targeting transcriptional addiction in Myc-driven lymphoma
- Dr Ashish Banerjee: Targeting iron homeostasis induces cell death via inhibition of autophagy
- Dr Shaun Fleming: Development of a trial program in Acute Lymphoblastic Leukaemia
- Prof Robert Medcalf: What are we targeting with anti-fibrinolytics?
- Breakout session: Enhancing linkages between lab and clinic
- Dr Jessica Morison: Real world management of lymphoma, the Lymphoma and Related Diseases Registry
- Dr Claire Dendle: Infections in patients with lymphoma
- A/Prof Matt McCormack: Lmo2 and Hhex - Roles in hematopoiesis and leukaemia
- Keynote Speaker: Prof Mark Dawson: Placing BETs on hold in AML
- Dr Mandy Davis: Mechanical Circulatory Support and Platelet Receptors
- Dr Anissa Jabbour: The differing toles of IKK1 and IKK2 in Haematopoiesis and Leukaemia
- Prof Andrew Spencer: Novel therapeutics and biomarkers in multiple myeloma
- Dr Cedric Tremblay: Presentation of Best Research Paper for 2016 Dynamin 2: the new central player in leukemogenesis and targeted therapy.
- Dr Marco Herold: CRISPR/Cas9 methodology to identify and validate novel cell death regulators for cancer therapy
No comments:
Post a Comment
Thankyou for your comment. We moderate all messages and may take a little time to review your comment. Please email inquiries to ccs.comms@monash.edu.